1. Scrip
  2. >>Business

Follow The Money, An Interactive Biotech Financing Map

 
• By Mike Ward and Alexandra Shimmings

In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.

MapCity
• Source: Shutterstock

Californian companies secured nearly half the $15.7bn that US biotechs attracted from venture and private sources in 2018 (Also see "Biotech Sector Raises $23bn In Venture Capital In 2018" - Scrip, 3 January, 2019.). The total raised by 134 Californian biotechs, across 139 separate venture transactions, came in just under $7.5bn. The largest fundraising was by the San Diego-based regenerative medicines company Samumed LLC, which raised $438m in an A-6 round. Since its creation in 2008, the company has raised a total of $650m at a valuation of $12bn.

Global biotech raises $22.83bn in 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

 
• By Mandy Jackson

While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By Joseph Haas

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

More from Scrip

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 
• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.